New drug combo aims to outsmart tough breast cancer
NCT ID NCT04265872
Summary
This early-phase trial is testing a new treatment strategy for metastatic triple-negative breast cancer that has stopped responding to standard chemotherapy. Researchers want to see if giving the drug bortezomib first can make the cancer more vulnerable to a later combination of pembrolizumab (an immunotherapy) and cisplatin (a chemotherapy). The study will enroll about 20 adult women to test the safety and initial effectiveness of this approach.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for BREAST CANCER are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Baylor University Medical Center, Baylor Charles A Sammons Cancer Center
RECRUITINGDallas, Texas, 75246, United States
Contact
Conditions
Explore the condition pages connected to this study.